This article compares two MedTech companies, Boston Scientific (BSX) and Abbott (ABT), evaluating them as potential investments. It details each company’s recent operational performance, strategic acquisitions, and financial metrics, including EPS estimates and price-to-sales ratios. While both are strong players in the MedTech sector with bullish analyst ratings, Abbott is presented as the more attractive option due to its current valuation and recent stock performance.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
This article compares two MedTech companies, Boston Scientific (BSX) and Abbott (ABT), evaluating them as potential investments. It details each company’s recent operational performance, strategic acquisitions, and financial metrics, including EPS estimates and price-to-sales ratios. While both are strong players in the MedTech sector with bullish analyst ratings, Abbott is presented as the more attractive option due to its current valuation and recent stock performance.